Dr. Abou-Alfa on Significance of RESORCE Trial for HCC

Ghassan K. Abou-Alfa, MD
Published: Tuesday, Jul 26, 2016


Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the significance of the RESORCE trial, which explored regorafenib (Stivarga) versus best supportive care for patients with unresectable hepatocellular carcinoma (HCC) who progressed after receiving sorafenib (Nexavar).

The RESORCE study is important for the HCC field because it demonstrates that patients have a promising option in the second-line treatment setting, Abou-Alfa explains.

This trial shows encouraging findings compared with prior studies, in which the placebo arms performed better in experimental arms, he adds.
 

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the significance of the RESORCE trial, which explored regorafenib (Stivarga) versus best supportive care for patients with unresectable hepatocellular carcinoma (HCC) who progressed after receiving sorafenib (Nexavar).

The RESORCE study is important for the HCC field because it demonstrates that patients have a promising option in the second-line treatment setting, Abou-Alfa explains.

This trial shows encouraging findings compared with prior studies, in which the placebo arms performed better in experimental arms, he adds.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x